Understanding Retinal Vasculitis Associated with Brolucizumab: Complex Pathophysiology or Occam's Razor?
作者信息
Sharma Ashish, Kumar Nilesh, Parachuri Nikulaa, Singh Sonali, Bandello Francesco, Regillo Carl D, Boyer David, Nguyen Quan Dong
机构信息
Lotus Eye Hospital and Institute, Coimbatore, India.
Ocular Pathologist, Madhavi Netralaya, Ara, India.
出版信息
Ocul Immunol Inflamm. 2022 Aug;30(6):1508-1510. doi: 10.1080/09273948.2021.1897628. Epub 2021 May 20.
Abstract
摘要
相似文献
1
Understanding Retinal Vasculitis Associated with Brolucizumab: Complex Pathophysiology or Occam's Razor?了解与布罗利尤单抗相关的视网膜血管炎：复杂的病理生理学还是奥卡姆剃刀原理？
Ocul Immunol Inflamm. 2022 Aug;30(6):1508-1510. doi: 10.1080/09273948.2021.1897628. Epub 2021 May 20.
2
[Intraocular inflammation with occlusive retinal vasculitis following intravitreal injection of brolucizumab].玻璃体内注射布罗珠单抗后发生的伴有闭塞性视网膜血管炎的眼内炎症
Ophthalmologe. 2022 Mar;119(3):296-299. doi: 10.1007/s00347-021-01341-4. Epub 2021 Feb 24.
3
Swept-source optical coherence tomography angiography of retinal occlusive vasculitis following brolucizumab administration: a case report.接受布罗利珠单抗治疗后视网膜阻塞性血管炎的扫频源光学相干断层扫描血管造影：病例报告。
BMC Ophthalmol. 2022 Jun 3;22(1):244. doi: 10.1186/s12886-022-02465-0.
4
Expert Opinion on Management of Intraocular Inflammation, Retinal Vasculitis, and Vascular Occlusion after Brolucizumab Treatment.关于布罗利珠单抗治疗后眼内炎症、视网膜血管炎和血管闭塞管理的专家意见
Ophthalmol Retina. 2021 Jun;5(6):519-527. doi: 10.1016/j.oret.2020.09.020. Epub 2020 Sep 29.
5
Risk of Inflammation, Retinal Vasculitis, and Retinal Occlusion-Related Events with Brolucizumab: Post Hoc Review of HAWK and HARRIER.Brolucizumab 相关炎症、视网膜血管炎和视网膜阻塞相关事件的风险：HAWK 和 HARRIER 的事后回顾。
Ophthalmology. 2021 Jul;128(7):1050-1059. doi: 10.1016/j.ophtha.2020.11.011. Epub 2020 Nov 15.
6
Three cases of brolucizumab-associated retinal vasculitis treated with systemic and local steroid therapy.三例与布罗鲁单抗相关的视网膜血管炎经全身和局部类固醇治疗。
Jpn J Ophthalmol. 2021 Mar;65(2):199-207. doi: 10.1007/s10384-021-00818-8. Epub 2021 Feb 5.
7
Re: Monés et al.: Risk of inflammation, retinal vasculitis, and retinal occlusion-related events with brolucizumab: post hoc review of HAWK and HARRIER (Ophthalmology. 2021;128:1050-1059).回复：莫内斯等人：布罗卢izumab治疗相关的炎症、视网膜血管炎和视网膜阻塞相关事件的风险：HAWK和HARRIER研究的事后分析（《眼科学》。2021年；128:1050 - 1059）。
Ophthalmology. 2021 Sep;128(9):e47. doi: 10.1016/j.ophtha.2021.04.029. Epub 2021 May 28.
8
Retinal Vasculitis and Intraocular Inflammation after Intravitreal Injection of Brolucizumab.眼内注射布罗鲁单抗后视网膜血管炎和眼内炎症。
Ophthalmology. 2020 Oct;127(10):1345-1359. doi: 10.1016/j.ophtha.2020.04.017. Epub 2020 Apr 25.
9
Association of Occlusive Retinal Vasculitis With Intravitreal Faricimab.闭塞性视网膜血管炎与玻璃体内注射法西单抗的关联。
JAMA Ophthalmol. 2024 May 1;142(5):489-491. doi: 10.1001/jamaophthalmol.2024.0928.
10
Early Experience With Brolucizumab Treatment of Neovascular Age-Related Macular Degeneration.布罗鲁单抗治疗新生血管性年龄相关性黄斑变性的早期经验
JAMA Ophthalmol. 2021 Apr 1;139(4):441-448. doi: 10.1001/jamaophthalmol.2020.7085.
引用本文的文献
1
Changes in Aqueous Humor Cytokine Profile Following Intravitreal Brolucizumab Injection.玻璃体内注射布罗珠单抗后房水细胞因子谱的变化。
Clin Ophthalmol. 2025 Feb 11;19:427-437. doi: 10.2147/OPTH.S504956. eCollection 2025.
2
Brolucizumab versus Aflibercept in Patients with Diabetic Macular Edema: A Meta-Analysis of Randomized Controlled Trials.布罗鲁单抗与阿柏西普治疗糖尿病性黄斑水肿的疗效比较：一项随机对照试验的荟萃分析
Clin Ophthalmol. 2024 Dec 10;18:3679-3690. doi: 10.2147/OPTH.S487055. eCollection 2024.
3
Bilateral occlusive retinal vasculitis secondary to intravitreal faricimab injection: a case report and review of literature.玻璃体内注射法西单抗继发双侧闭塞性视网膜血管炎：一例报告并文献复习
Eye Vis (Lond). 2024 Dec 3;11(1):48. doi: 10.1186/s40662-024-00416-y.
4
Retinal vasculitis after intravitreal aflibercept 8 mg for neovascular age-related macular degeneration.玻璃体内注射阿柏西普 8mg 治疗新生血管性年龄相关性黄斑变性后视网膜血管炎。
Jpn J Ophthalmol. 2024 Sep;68(5):531-537. doi: 10.1007/s10384-024-01107-w. Epub 2024 Aug 20.
5
Brolucizumab-associated intraocular inflammation in Indian patients by VRSI study group.由 VRSI 研究小组报告的印度患者中与 brolucizumab 相关的眼内炎症。
Indian J Ophthalmol. 2024 Aug 1;72(8):1156-1161. doi: 10.4103/IJO.IJO_2973_23. Epub 2024 Jul 29.
6
Factors Associated With Intraocular Inflammation in Neovascular Age-Related Macular Degeneration Patients Treated With Brolucizumab.与接受 Brolucizumab 治疗的新生血管性年龄相关性黄斑变性患者眼内炎症相关的因素。
Invest Ophthalmol Vis Sci. 2024 Jan 2;65(1):8. doi: 10.1167/iovs.65.1.8.
7
Beovu, but not Lucentis impairs the function of the barrier formed by retinal endothelial cells in vitro.贝伐珠单抗（Beovu）会损害体外培养的视网膜内皮细胞形成的屏障功能，但雷珠单抗（Lucentis）不会。
Sci Rep. 2022 Jul 21;12(1):12493. doi: 10.1038/s41598-022-16770-7.
8
Swept-source optical coherence tomography angiography of retinal occlusive vasculitis following brolucizumab administration: a case report.接受布罗利珠单抗治疗后视网膜阻塞性血管炎的扫频源光学相干断层扫描血管造影：病例报告。
BMC Ophthalmol. 2022 Jun 3;22(1):244. doi: 10.1186/s12886-022-02465-0.
9
Bilateral blindness after uneventful brolucizumab injection for macular degeneration.接受无事件布鲁珠单抗注射治疗黄斑变性后出现双侧失明。
BMC Ophthalmol. 2022 Feb 16;22(1):80. doi: 10.1186/s12886-022-02305-1.
10
Initial Pro Re Nata Brolucizumab for Exudative AMD: The PROBE Study.初始按需使用布罗珠单抗治疗渗出性年龄相关性黄斑变性：PROBE研究。
J Clin Med. 2021 Sep 15;10(18):4153. doi: 10.3390/jcm10184153.
本文引用的文献
1
Brolucizumab-related retinal vasculitis with exacerbation following ranibizumab retreatment: A clinicopathologic case study.布罗鲁单抗相关的视网膜血管炎伴雷珠单抗再次治疗后病情加重：一项临床病理病例研究。
Am J Ophthalmol Case Rep. 2020 Nov 10;20:100989. doi: 10.1016/j.ajoc.2020.100989. eCollection 2020 Dec.
2
Risk of Inflammation, Retinal Vasculitis, and Retinal Occlusion-Related Events with Brolucizumab: Post Hoc Review of HAWK and HARRIER.Brolucizumab 相关炎症、视网膜血管炎和视网膜阻塞相关事件的风险：HAWK 和 HARRIER 的事后回顾。
Ophthalmology. 2021 Jul;128(7):1050-1059. doi: 10.1016/j.ophtha.2020.11.011. Epub 2020 Nov 15.
3
Expert Opinion on Management of Intraocular Inflammation, Retinal Vasculitis, and Vascular Occlusion after Brolucizumab Treatment.关于布罗利珠单抗治疗后眼内炎症、视网膜血管炎和血管闭塞管理的专家意见
Ophthalmol Retina. 2021 Jun;5(6):519-527. doi: 10.1016/j.oret.2020.09.020. Epub 2020 Sep 29.
4
Occlusive Retinal Vasculitis Following Intravitreal Brolucizumab.玻璃体内注射布罗珠单抗后发生的视网膜血管阻塞性血管炎
J Vitreoretin Dis. 2020 Jul;4(4):269-279. doi: 10.1177/2474126420930863. Epub 2020 Jul 1.
5
Retinal Vasculitis and Intraocular Inflammation after Intravitreal Injection of Brolucizumab.眼内注射布罗鲁单抗后视网膜血管炎和眼内炎症。
Ophthalmology. 2020 Oct;127(10):1345-1359. doi: 10.1016/j.ophtha.2020.04.017. Epub 2020 Apr 25.
6
Severe vision loss secondary to retinal arteriolar occlusions after multiple intravitreal brolucizumab administrations.多次玻璃体内注射布罗珠单抗后继发视网膜小动脉阻塞导致严重视力丧失。
Am J Ophthalmol Case Rep. 2020 Apr 2;18:100687. doi: 10.1016/j.ajoc.2020.100687. eCollection 2020 Jun.
7
Retinal arterial occlusive vasculitis following intravitreal brolucizumab administration.玻璃体内注射布罗珠单抗后发生的视网膜动脉闭塞性血管炎。
Am J Ophthalmol Case Rep. 2020 Mar 31;18:100680. doi: 10.1016/j.ajoc.2020.100680. eCollection 2020 Jun.
8
Brolucizumab and immunogenicity.布罗鲁单抗与免疫原性。
Eye (Lond). 2020 Oct;34(10):1726-1728. doi: 10.1038/s41433-020-0853-9. Epub 2020 Apr 6.
9
Brolucizimab-leading an era of structural revolution for long-term VEGF suppression.布罗鲁单抗——引领长期抑制血管内皮生长因子的结构革命时代。
Eye (Lond). 2020 Apr;34(4):611-613. doi: 10.1038/s41433-019-0583-z. Epub 2019 Sep 19.
10
Brolucizumab: is extended VEGF suppression on the horizon?布罗利珠单抗：长效血管内皮生长因子抑制即将实现？
Eye (Lond). 2020 Mar;34(3):424-426. doi: 10.1038/s41433-019-0582-0. Epub 2019 Sep 16.
Zotero 插件